25 results
8-K
EX-99.1
ATXI
Avenue Therapeutics, Inc.
15 May 24
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9:01am
for SBMA)
In April, Avenue hosted a virtual key opinion leader (“KOL”) event highlighting expert perspectives on SBMA. The event featured
424B4
ATXI
Avenue Therapeutics, Inc.
2 Nov 23
Prospectus supplement with pricing info
9:00am
whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice
8-K
EX-1.1
mnpgje
13 Dec 21
Entry into a Material Definitive Agreement
9:23am
8-K
EX-1.1
gzakmj9zpsjn0xfppk
10 Nov 21
Entry into a Material Definitive Agreement
5:22pm
8-K
EX-3.1
r48rn0i nick
11 Feb 19
Entry into a Material Definitive Agreement
8:39am
DEFM14A
cfndzxun4pz jlaoenb
21 Dec 18
Proxy related to merger
12:23pm
PREM14A
xwrfiosm9wuuyf h2u
11 Dec 18
Preliminary proxy related to merger
5:23pm